Presentation is loading. Please wait.

Presentation is loading. Please wait.

ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR

Published byClifton White Modified over 9 years ago

Similar presentations

Presentation on theme: "ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR"— Presentation transcript:

1 ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR
mDR (Mo) mPFS (Mo) PFS rate mOS (Mo) OS rate CheckMate-017 III Adv. SQ-NSCLC 2nd 135
137 N3 q2wk
T q3wk OS 6.0 8% (2-Yr) CheckMate-057 Adv. NS-NSCLC 290 9.5 16% (2-Yr) CheckMate-012 I Adv. NSCLC 1st 39 N3 q2wk + I1 x q6wk Safety 31% 8.3 NC (24-Wk) CheckMate-032 I/II Rec. SCLC ≧2nd 53 N3+I1 —> N3 q2wk 31% 3.4 7.8 48% (1-Yr) CheckMate-205 Ib Cohort B: failed BV after ASCT 3rd 80 N3 q2wk 66% 79% (6-Mo) 99% (6-Mo) CheckMate-142 II MSI-H mCRC Mostly ≧3rd 26 N3+I1 q3wk x 4 —> N3 q2wk 4% NR NR 80% (4-Mo) NR 100% (5-Mo) CheckMate-067 Adv. Melanoma 315 I3 q3wk x 4 —> Placebo PFS & OS 19.0% 14.4 2.9 CheckMate-064 UNK 68
70 I3 q3wk x 4 —> N3 q2wk x 6 —> N3 q2wk 31% 16.9 76% (1-Yr)
54% (1-Yr) Treatments Legend: I1: ipilimumab 1 mg/kg; I3: ipilimumab 3 mg/kg; N1: nivolumab 1 mg/kg; N3: nivolumab 3 mg/kg; T: docetaxel 75 mg/m2. Abbreviations: 1o EP = Primary Endpoint; Adv. = Advanced; ASCT = Autologous Cell Transplant; BV = brentuximab vendotin; CHL = Classical Hodgkin Lymphoma; mCRC = Metastatic Colorectal Cancer; mDR = median Duration Response; mOS = median Overall Survival; Mo = Months; mPFS = median Progression Free Survival; MSI-H = High Micro Satellite Instability; NC = Not Calculated; NR = Not Reached; NSCLC = non-small cell lung cancer; NS-NSCLC = Non-squamous NSCLC; ORR = Overall Response Rate; Ph = Phase; PI = Principal Investigator; qXwk = every X weeks; Rec. = Recurrent; SQ-NSCLC = squamous NSCLC; UNK = Unknown; Wk = Weeks; Yr = Year. MediPaper

2 Courtesy of MediPaper Medical Writers - Medi-Paper.com
ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR (Mo) mPFS (Mo) PFS rate mOS (Mo) OS rate CheckMate-017 III Adv. SQ-NSCLC 2nd 135
137 N3 q2wk
T q3wk OS 6.0 8% (2-Yr) CheckMate-057 Adv. NS-NSCLC 290 9.5 16% (2-Yr) CheckMate-012 I Adv. NSCLC 1st 39 N3 q2wk + I1 x q6wk Safety 31% 8.3 NC (24-Wk) CheckMate-032 I/II Rec. SCLC ≧2nd 53 N3+I1 —> N3 q2wk 31% 3.4 7.8 48% (1-Yr) CheckMate-205 Ib Cohort B: failed BV after ASCT 3rd 80 N3 q2wk 66% 79% (6-Mo) 99% (6-Mo) CheckMate-142 II MSI-H mCRC Mostly ≧3rd 26 N3+I1 q3wk x 4 —> N3 q2wk 4% NR NR 80% (4-Mo) NR 100% (5-Mo) CheckMate-067 Adv. Melanoma 315 I3 q3wk x 4 —> Placebo PFS & OS 19.0% 14.4 2.9 CheckMate-064 UNK 68
70 I3 q3wk x 4 —> N3 q2wk x 6 —> N3 q2wk 31% 16.9 76% (1-Yr)
54% (1-Yr) Treatments Legend: I1: ipilimumab 1 mg/kg; I3: ipilimumab 3 mg/kg; N1: nivolumab 1 mg/kg; N3: nivolumab 3 mg/kg; T: docetaxel 75 mg/m2. Abbreviations: 1o EP = Primary Endpoint; Adv. = Advanced; ASCT = Autologous Cell Transplant; BV = brentuximab vendotin; CHL = Classical Hodgkin Lymphoma; mCRC = Metastatic Colorectal Cancer; mDR = median Duration Response; mOS = median Overall Survival; Mo = Months; mPFS = median Progression Free Survival; MSI-H = High Micro Satellite Instability; NC = Not Calculated; NR = Not Reached; NSCLC = non-small cell lung cancer; NS-NSCLC = Non-squamous NSCLC; ORR = Overall Response Rate; Ph = Phase; PI = Principal Investigator; qXwk = every X weeks; Rec. = Recurrent; SQ-NSCLC = squamous NSCLC; UNK = Unknown; Wk = Weeks; Yr = Year. Courtesy of MediPaper Medical Writers - Medi-Paper.com

Download ppt "ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR"

Similar presentations

Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Moskowitz CH et al. Proc ASH 2014;Abstract 290.
ASCO G.U. 2014 Lawrence H. Einhorn.

ASCO G.U Lawrence H. Einhorn.
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
LaCasce A et al. Proc ASH 2014;Abstract 293.

LaCasce A et al. Proc ASH 2014;Abstract 293.
Ansell SM et al. N Engl J Med 2015;372(4):311-9.

Ansell SM et al. N Engl J Med 2015;372(4):311-9.
Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab:

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab:
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Antiangiogenic Agents in Advanced NSCLC Jared Weiss, MD Assistant Professor of Medicine Division of Hematology and Oncology University of North Carolina.

Antiangiogenic Agents in Advanced NSCLC Jared Weiss, MD Assistant Professor of Medicine Division of Hematology and Oncology University of North Carolina.
Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.

Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.
A single-arm phase II trial in p treated with C, D and B (15 mg/kg) every 3 weeks followed by B showed a promising efficacy, in terms of progression free.

A single-arm phase II trial in p treated with C, D and B (15 mg/kg) every 3 weeks followed by B showed a promising efficacy, in terms of progression free.
Bevacizumab Update.

Bevacizumab Update.
Www.OncologyEducation.com ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib.

Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib.
Www.OncologyEducation.ca Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
FOLFOX4 with or without Bevacizumab in Previously Treated Advanced Colorectal Cancer: Results from ECOG-E3200 Lee M Ellis, MD Colorectal Cancer Update.

FOLFOX4 with or without Bevacizumab in Previously Treated Advanced Colorectal Cancer: Results from ECOG-E3200 Lee M Ellis, MD Colorectal Cancer Update.

Similar presentations

Ads by Google